Research the Cure webinar – Phase III trial for a topical whole body treatment for EB

Phase III trial for a topical whole body treatment for EB patients with Simplex, Recessive Dystrophic and Junctional EB

Join Sharmila as she talks to Dr Robert Ryan, Founder and CEO of Paradigm Therapeutics about a phase III clinical trial for a topical cream they are developing.

When? Wednesday 23rd September, 1.30pm BST

Where? Online – register now

Who? This webinar is open to all – EB patients and families, researchers, clinicians, and anyone with an interest in EB. The webinar is free to join.

Please note that this is a live event only – a recording won’t be shared after the event.

Dr. Robert Ryan

Robert is the CEO of Paradigm Therapeutics which is focused on the development of a topical therapy for the whole skin surface treatment of Epidermolysis Bullosa (EB) in patients across the 3 main subtypes, namely Simplex, Dystrophic and Junctional. He has more than 35 years of research/pharmaceutical/biotech experience, spanning the global development process from preclinical through Phase IV, including over 20 years of involvement with EB families.

Robert previously held senior regulatory positions at three of the top five leading clinical development companies (CRO’s), PPD, INC Research, and Quintiles.  His diverse pharmaceutical career covered senior preclinical, regulatory and clinical positions with Roche, Bristol-Myers Squibb (BMS), UCB, Atherogenics, and Pfizer.